Medtronic have officially spun off its diabetes business into a new standalone company called MiniMed.
MiniMed spin-off
The new company have launched with a share offering raising around $560 million through the sale of shares.
Medtronic first announced plans to spin off the diabetes division in 2025 as part of a strategy to create a focused diabetes technology company that can compete more directly with firms such as Dexcom, Insulet and Tandem Diabetes Care.
The standalone MiniMed company is expected to include Medtronic’s insulin pump portfolio, CGM technologies and automated insulin delivery systems.
Product and regulatory updates
In February, the US Food and Drug Administration (FDA) cleared additional uses for the MiniMed 780G system, Medtronic’s hybrid-closed loop insulin pump. The clearance allows the system to be used with ultra-rapid-acting insulins including Fiasp and Lyumjev.
The FDA also cleared the MiniMed 780G system for use with the Instinct sensor, a CGM developed by Abbott specifically for integration with Medtronic pumps. The system can now be used by people with insulin-requiring type 2 diabetes as well as those with type 1 diabetes.
The MiniMed 780G system adjusts insulin delivery every five minutes using glucose readings from the connected sensor. The Instinct sensor can be worn for up to 15 days and provides another sensor option for users of the pump alongside Medtronic’s own Guardian and Simplera sensors.
Medicare access in the United States has also expanded to include the MiniMed 780G system paired with the Instinct sensor, which could increase uptake among older adults using insulin therapy.
UK and international context
Outside the United States, the MiniMed 780G system already has regulatory approval in Europe and is available in many countries including the UK.
However, the Instinct sensor that integrates Abbott glucose sensing technology with the MiniMed pump has so far launched in the United States and there has been no confirmed timeline for availability in Europe.
The planned MiniMed spin-off will also create a standalone global diabetes technology company. The new business is expected to include several thousand employees and operate across international markets including Europe.
__________
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website whatcgm.comdoes not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.